In addition to the typical manifestations of XP/CS, the patient with the XP/CS phenotype caused by a novel ERCC5 mutation reported in this article developed severe and progressive liver dysfunction after drug induction. This evidence concerns the gene ERCC5 and Cowden syndrome 1.